

| Results for announcement to the market   |  |                         |
|--|--|-------------------------|
| Name of issuer   | Rua Bioscience Limited                       |                         |
| Reporting Period   | 6 months to 31 December 2024                 |                         |
| Previous Reporting Period  | 6 months to 31 December 2023                 |                         |
| Currency   | NZD  |                         |
|  | Amount (000s)                                | Percentage change       |
| Revenue from continuing operations   | \$889  | 529%                    |
| Total Revenue  | \$889  | 529%                    |
| Net profit/(loss) from continuing operations   | (\$1,802)                                    | 83%                     |
| Total net profit/(loss)  | (\$1,802)                                    | 83%                     |
| Interim/Final Dividend   |  |                         |
| Amount per Quoted Equity Security  | Not proposing to pay a dividend              |                         |
| Imputed amount per Quoted Equity Security  | Not Applicable                               |                         |
| Record Date  | Not Applicable                               |                         |
| Dividend Payment Date  | Not Applicable                               |                         |
|  | Current period                               | Prior comparable period |
| Net tangible assets per Quoted Equity Security   | \$0.02                                       | \$0.05                  |
| A brief explanation of any of the figures above necessary to enable the figures to be understood | Refer unaudited interim financial statements |                         |
| Authority for this announcement  |  |                         |
| Name of person authorised to make this announcement  | Paul Naske                                   |                         |
| Contact person for this announcement   | Paul Naske                                   |                         |
| Contact phone number   | +64 (21) 445 154                             |                         |
| Contact email address  | paul.naske@ruabio.com                        |                         |
| Date of release through MAP  | 28 February 2025                             |                         |

Unaudited financial statements accompany this announcement.